Daily Magnesium Intake and Hypermagnesemia in Hemodialysis Patients With Chronic Kidney Disease

Objective: The aim of this study was to evaluate daily magnesium intake and the relation to its serum concentration in hemodialysis (HD) patients with chronic kidney disease (CKD). Design: This is a prospective, open-label, cross-sectional clinical study analyzing daily magnesium intake based on nutritional questionnaire. Participants: A total of 101 HD patients with CKD were screened for hypermagnesemia. All patients with serum magnesium >1.5 mmol/L were asked to fill in the standard 3-day nutritional questionnaire. The control group consisted of twice as many randomly selected HD patients with serum magnesium concentration <1.5 mmol/L and 20 subjects with normal kidney function on usual diet. Results: Mean (+/- standard deviation) serum magnesium concentration in HD patients was 1.32 +/- 0.18 mmol/L. Hypermagnesemia >1.5 mmol/L was found in 17 (16.8%) patients. There was no one case of severe hypermagnesemia (>2.0 mmol/L). The daily intake of magnesium was higher by 31.7% in the group with serum magnesium >1.5 mmol/L. Hypermagnesemia was observed in patients ingesting >281 mg of magnesium daily. In univariate analysis, there was a strong positive correlation between magnesium intake and serum concentration in the whole group (r = 0.870, P < .001). No correlation between Kt/V or residual diuresis and serum magnesium concentration was found. Conclusions: Magnesium consumption is the most important determinant of serum magnesium concentration in HD patients with CKD. Magnesium-containing phosphate binders can be considered in the therapy of hyperphosphatemia in HD patients without hypermagnesemia. (C) 2012 by the National Kidney Foundation, Inc. All rights reserved.